Personalized VLNT: Matching Donor Site and Surgical Strategy to a Patient's Lymphedema Genotype

The vascularized lymph node transfer (VLNT) is only as good as the donor site chosen for each patient. With genetic testing now routine in advanced lymphedema centers, donor site selection has become a personalized decision driven by the patient’s underlying mutation and lymphatic reserve.

The main donor sites and what they offer

• Groin (superficial inguinal) — high node count, hidden scar, but iatrogenic lymphedema risk if reverse mapping is omitted.
• Supraclavicular — moderate node count, robust pedicle, low donor morbidity.
• Submental — small but lymphangiogenically potent flap; favored in upper-limb lymphedema.
• Omental / gastroepiploic — large lymphoid mass, ideal for severe disease, requires laparoscopy.
• Lateral thoracic — useful as a second-line flap, modest node count.
• Mesenteric / jejunal — emerging option for refractory cases.

Genotype-driven donor site logic

FLT4 (Milroy)

Hypoplastic initial lymphatics demand a donor flap with maximum lymphangiogenic drive. The omental flap (high VEGF-C-rich nodal mass) or supraclavicular flap are preferred. Avoid small-volume submental flaps as the sole transfer.

FOXC2 (Lymphedema-distichiasis)

The problem is valve incompetence, not vessel scarcity. A moderate-volume flap (supraclavicular or submental) placed distally at the wrist or ankle works well — the flap acts as a new pump and capacitor.

GJC2

Impaired contractility benefits from a flap that adds drainage rather than relying on host pumping. Omental or groin flaps with generous parenchyma are favored. Postoperative CDT is essential.

PIEZO1, CCBE1, SOX18

Generalized dysplasia means most donor sites are themselves abnormal. If surgery is offered at all, the omentum is preferred because intra-abdominal lymphatic tissue is often less affected than peripheral nodes.

Secondary lymphedema with normal genetics

Standard rules apply — match donor site to recipient territory and surgical access. Reverse lymphatic mapping at the groin is mandatory.

Combining VLNT with adjuncts

• LVA — for patients with preserved collectors (most FOXC2, many secondary cases).
• Liposuction-assisted lymphedema treatment (LALT) — for solid, fibrotic late-stage limbs after VLNT has matured.
• Pharmacologic adjuncts — emerging VEGF-C and ketoprofen-based protocols, especially in hypoplastic phenotypes.

Outcome expectations by genotype

Realistic counseling matters. FOXC2 patients often see 40–60% volume reduction at 24 months. FLT4 patients typically see 20–35% with combined VLNT + LVA. Generalized dysplasias rarely exceed 10–20%, and surgery should focus on infection reduction and quality of life rather than volume.

Conclusion

There is no universal “best” donor site for VLNT. The right flap is the one that matches the patient’s lymphatic biology — and that biology is now readable from a simple genetic panel. Personalized donor-site selection is the next step in turning lymphedema surgery from hopeful into predictable.